U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07023666) titled 'Early Screening and Treatment of Heart Complication in Sickle Cell Disease' on June 09.
Brief Summary: This study tests whether early heart screening and treatment for iron overload in subjects with sickle cell disease can prevent heart problems and reduce hospitalizations.
Study Start Date: June 30
Study Type: INTERVENTIONAL
Condition:
Sickle Cell Disease
Intervention:
DRUG: Deferoxamine
Deferoxamine is used to reduce excess iron accumulation after monitoring iron levels. Adjustment to therapy will be based on iron burden assessments throughout the study duration.
DRUG: Deferasirox
Deferasirox is used for iron chelation th...